• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jun 13, 2024 at 11:22: PM
via The failure of another trial adds to uncertainty around the effectiveness of Duchenne gene therapy, though analysts don’t believe it’ll affect the FDA’s decision to widen use of Sarepta’s Elevidys.

article source
 




Top Bottom
Back
Quote